Roche plans Phase III trial for diabetes candidate aleglitazar
This article was originally published in Scrip
Executive Summary
Roche is to begin Phase III studies of its oral peroxisome proliferator-activated receptor (PPAR) α/γ co-agonist aleglitazar (R1439) in patients with type 2 diabetes during the second half of this year, following positive results in a Phase II trial which were published in The Lancet on June 9th, and presented at the American Diabetes Association (ADA) meeting in New Orleans.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.